Current Report Filing (8-k)
March 09 2017 - 04:27PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
March 9, 2017
PEREGRINE
PHARMACEUTICALS, INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
|
001-32839
|
|
95-3698422
|
(State of other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
14282 Franklin Avenue, Tustin, California 92780
|
(Address of Principal Executive Offices)
|
|
|
|
|
|
Registrant’s telephone number, including area code:
(714) 508-6000
|
|
Not Applicable
|
(Former name or former address, if changed since last report)
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
o
Soliciting material pursuant to Rule 14A-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
On March 9, 2017, Peregrine
Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the declaration by the Company’s Board
of Directors of a quarterly cash dividend payment of $0.65625 per share (the “Dividend”) on the Company’s 10.50%
Series E Convertible Preferred Stock (the “Series E Preferred Stock”), accruing from January 1, 2017 through March
31, 2017. The Dividend equates to an annualized 10.50% per share of Series E Preferred Stock based on the $25.00 per share stated
liquidation preference. The Dividend on the Series E Preferred Stock is payable on April 3, 2017 to holders of record at the close
of business on March 20, 2017. A copy of the press release is filed hereto as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. The following material is
filed as an exhibit to this Current Report on Form 8-K:
Exhibit
Number
99.1 Press
Release issued March 9, 2017.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
PEREGRINE PHARMACEUTICALS, INC.
|
|
|
|
|
Date: March 9, 2017
|
By:
|
/s/ Paul J. Lytle
|
|
|
Paul J. Lytle
Chief Financial
Officer
|
EXHIBIT INDEX
Exhibit
Number
|
|
Description
|
|
|
|
99.1
|
|
Press Release issued March 9, 2017.
|
Exhibit 99.1
Contacts:
|
|
|
Stephanie Diaz (Investors)
|
Tim Brons (Media)
|
|
Vida Strategic Partners
|
Vida Strategic Partners
|
|
415-675-7401
|
415-675-7402
|
|
sdiaz@vidasp.com
|
tbrons@vidasp.com
|
|
PEREGRINE PHARMACEUTICALS DECLARES QUARTERLY
DIVIDEND ON ITS SERIES E CONVERTIBLE PREFERRED STOCK
TUSTIN, Calif., March 9, 2017
--
Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP) today announced that its Board of Directors has declared a quarterly
cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock").
The quarterly dividend on the Series E
Preferred Stock is payable on April 3, 2017 to holders of record at the close of business on March 20, 2017.
The quarterly dividend payment on the Series
E Preferred Stock will be $0.65625 per share, which is equivalent to an annualized 10.50% per share, based on the $25.00 per share
stated liquidation preference, accruing from January 1, 2017 through March 31, 2017. The Series E Preferred Stock is listed on
the NASDAQ Capital Market and trades under the ticker symbol "PPHMP".
About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical
company committed to improving the lives of patients by delivering high quality pharmaceutical products through its contract development
and manufacturing organization (CDMO) services and through advancing and licensing its investigational immunotherapy and related
products. Peregrine's in-house CDMO services, including cGMP manufacturing and development capabilities, are provided through
its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services
for both Peregrine and third-party customers. The company is also working to evaluate its lead immunotherapy candidate, bavituximab,
in combination with immune stimulating therapies for the treatment of various cancers, and developing its proprietary exosome technology
for the detection and monitoring of cancer. For more information, please visit www.peregrineinc.com.
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Mar 2023 to Mar 2024